(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock indexes rose on Friday and were on track for their best weekly performance since October. The Dow Jones industrial average was up 0.96 percent at 17,903.55, the S&P 500 was up 0.69 percent at 2,095.66 and the Nasdaq Composite was up 0.64 percent at 5,106.267.
** BIOMARIN PHARMACEUTICAL INC, $98.595, -4.38 pct
** SAREPTA THERAPEUTICS INC, $32.9017, +26.21 pct
** PTC THERAPEUTICS INC, $28.5, -5.38 pct
U.S. Food and Drug Administration staff reviewers said clinical data to date did not merit approving the drug developer’s muscle-wasting disorder drug.
Shares of Sarepta, which is developing rival product for DMD, rose. Shares of PTC, whose experimental DMD drug has also failed a late-stage study, fell.
** SPRINT CORP, $3.81, -5.93 pct
The company said it would raise about $1.1 billion in cash by selling and then leasing back some leased-out mobile devices to a company whose backers include SoftBank Group Corp. Sprint also cut its full-year adjusted EBITDA forecast to $6.8 billion-$7.1 billion from $7.2 billion-$7.6 billion, based on the deal and the inclusion of “transformation program costs.”
** ABERCROMBIE & FITCH, $23.29, +19.50 pct
The teen apparel retailer said its quarterly profit more than doubled and same-store sales fell less than expected as company boosted gross margin by offering fewer promotions and controlling costs.
** NIKE INC, $132.46, +5.31 pct
The world’s No. 1 sportswear maker said its board approved a new $12 billion share buyback program and a two-for-one split of its class A and class B shares.
** FOOT LOCKER INC, $64.51, +4.84 pct
The footwear retailer reported better-than-expected quarterly profit and sales, helped by strong demand for basketball and running shoes.
** HORIZON PHARMA PLC, $20.26, +7.65 pct
** DEPOMED INC, $18.99, -2.06 pct
The Ireland-based drugmaker said it had withdrawn its offer to acquire Depomed following a court ruling that granted Depomed’s motion for preliminary injunctive relief on Horizon’s alleged used of confidential information.
** PEABODY ENERGY CORP, $11.73, -0.93 pct
** CLOUD PEAK ENERGY INC, $2.91, -3.96 pct
** CONSOL ENERGY INC, $7.74, -1.15 pct
UBS cut its long-term sea-borne thermal coal price forecast by 33 percent and hard coking coal price forecast by 20 percent due to lack of growth in sea-borne demand and expectations of deflated capital and operating expenses.
** APTOSE BIOSCIENCES INC, $3.71, -30.13 pct
The drug developer said the U.S. Food and Drug Administration put its early-stage trial on a cancer drug on hold after a review found a malfunctioning infusion pump at a clinical site where the tests were being held.
** KALOBIOS PHARMACEUTICALS INC, $20.95, +101.44 pct
The drug developer said it appointed Martin Shkreli CEO after the controversial head of Turing Pharmaceuticals led a group of investors to buy 70 percent of its outstanding shares.
** MENTOR GRAPHICS CORP, $19.16, -31.03 pct
JP Morgan rated Mentor’s stock “sell” after the electronic hardware and software design provider set its fourth-quarter and full-year revenue forecasts below Wall Street estimates.
** NIMBLE STORAGE INC, $10.88, -46.64 pct
The data storage maker reported bigger-than-expected quarterly loss as it shifts to flash-centric architectures from disk-centric architectures.
** HABIT RESTAURANTS INC, $23.095, +6.14 pct
The fast-casual burger chain operator postponed its previously announced secondary offering “in light of current capital market conditions”.
** BUILDERS FIRSTSOURCE INC, $13.3, -1.92 pct
The building products supplier said shareholder Warburg Pincus would offer 7 million shares. Builders FirstSource had 109.3 million shares outstanding as of Tuesday, according to Thomson Reuters data.
** PFIZER INC, $32.405, +0.36 pct
** ALLERGAN PLC, $311.28, +3.06 pct
Pfizer is negotiating a 2-3 percent break-up fee with Allergan, people familiar with the matter said. If Pfizer were to walk away from Allergan, it would have to pay $3 billion to $4.5 billion based on a $150 billion deal value, making it one of the highest ever break-up fees in dollar terms.
** INTUIT INC, $102.74, +5.46 pct
The tax-preparation software maker estimated full-year adjusted profit of $3.45-$3.50 per share, above the average analyst estimate of $3.43.
** ROSS STORES INC, $50.1, +8.44 pct
At least 3 brokerages raised their price targets by as much as $2 to as high as $61 after the off-price retailer increased its full-year 2015 profit forecast to $2.45-$2.48 per share from $2.40-$2.45
** WORKDAY INC, $81.59, -3.21 pct
The human resources software maker forecast current-quarter revenue below analysts’ estimates and reported a bigger net loss for the third quarter.
** NATIONAL BANK OF GREECE, $0.2666, -28.14 pct
The troubled Greek lender priced its share offering at 0.02 euros per share, or at 0.30 euros per share reflecting 1-for-15 reverse share split.
Reporting by Nikhil Subba in Bengaluru; Editing by Kirti Pandey